CA2590293A1 - Utilisation du composant neurotoxique du botulinum pour le traitement d'un muscle spastique - Google Patents

Utilisation du composant neurotoxique du botulinum pour le traitement d'un muscle spastique

Info

Publication number: CA2590293A1
Authority: CA; Canada
Prior art keywords: botulinum; treat; botulinum toxin; neurotoxic component; spastic muscle
Prior art date: 1993-12-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA002590293A

Other languages

English (en)

Other versions

CA2590293C (fr

Inventor

Michael W. Grayston

Judith M. Leon

Steven R. Carlson

K. Roger Aoki

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Allergan Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-28

Filing date

1994-12-16

Publication date

1995-07-06

1994-12-16 Application filed by Individual filed Critical Individual

1994-12-16 Priority claimed from CA002300766A external-priority patent/CA2300766C/fr

1995-07-06 Publication of CA2590293A1 publication Critical patent/CA2590293A1/fr

2009-05-12 Application granted granted Critical

2009-05-12 Publication of CA2590293C publication Critical patent/CA2590293C/fr

2014-12-16 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

210000003205 muscle Anatomy 0.000 title 1
231100000189 neurotoxic Toxicity 0.000 title 1
230000002887 neurotoxic effect Effects 0.000 title 1
230000001148 spastic effect Effects 0.000 title 1
108030001720 Bontoxilysin Proteins 0.000 abstract 2
229940053031 botulinum toxin Drugs 0.000 abstract 2
230000028327 secretion Effects 0.000 abstract 2
206010023644 Lacrimation increased Diseases 0.000 abstract 1
208000007101 Muscle Cramp Diseases 0.000 abstract 1
208000029578 Muscle disease Diseases 0.000 abstract 1
208000021642 Muscular disease Diseases 0.000 abstract 1
208000005392 Spasm Diseases 0.000 abstract 1
210000002565 arteriole Anatomy 0.000 abstract 1
230000001713 cholinergic effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
210000000232 gallbladder Anatomy 0.000 abstract 1
210000005095 gastrointestinal system Anatomy 0.000 abstract 1
230000004317 lacrimation Effects 0.000 abstract 1
210000003097 mucus Anatomy 0.000 abstract 1
230000004118 muscle contraction Effects 0.000 abstract 1
210000000664 rectum Anatomy 0.000 abstract 1
210000002460 smooth muscle Anatomy 0.000 abstract 1
210000005070 sphincter Anatomy 0.000 abstract 1
230000035900 sweating Effects 0.000 abstract 1
230000002485 urinary effect Effects 0.000 abstract 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002590293A 1993-12-28 1994-12-16 Utilisation du composant neurotoxique du botulinum pour le traitement d'un muscle spastique Expired - Lifetime CA2590293C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17399693A	1993-12-28	1993-12-28
US08/173,996		1993-12-28
CA002300766A CA2300766C (fr)	1993-12-28	1994-12-16	Methode pour traiter une secretion cholinergique influencee

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002300766A Division CA2300766C (fr)	1993-12-28	1994-12-16	Methode pour traiter une secretion cholinergique influencee

Publications (2)

Publication Number	Publication Date
CA2590293A1 true CA2590293A1 (fr)	1995-07-06
CA2590293C CA2590293C (fr)	2009-05-12

Family

ID=38236376

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
CA002590293A Expired - Lifetime CA2590293C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique du botulinum pour le traitement d'un muscle spastique
CA002589987A Expired - Fee Related CA2589987C (fr)	1993-12-28	1994-12-16	Methode pour traiter une secretion cholinergique influencee
CA002590537A Expired - Lifetime CA2590537C (fr)	1993-12-28	1994-12-16	Utilisation de la composante neurotoxique de la toxine botulinique pour le traitement du larmoiement excessif
CA002589989A Expired - Lifetime CA2589989C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique de la toxine botulinique pour traiter la sudation excessive
CA002589968A Abandoned CA2589968A1 (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique de la toxine botulinique pour traiter des douleurs associees a l'activite ou la contracture musculaire
CA002590540A Expired - Lifetime CA2590540C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique d'une toxine botulinique pour le traitement de secretions muqueuses excessives

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
CA002589987A Expired - Fee Related CA2589987C (fr)	1993-12-28	1994-12-16	Methode pour traiter une secretion cholinergique influencee
CA002590537A Expired - Lifetime CA2590537C (fr)	1993-12-28	1994-12-16	Utilisation de la composante neurotoxique de la toxine botulinique pour le traitement du larmoiement excessif
CA002589989A Expired - Lifetime CA2589989C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique de la toxine botulinique pour traiter la sudation excessive
CA002589968A Abandoned CA2589968A1 (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique de la toxine botulinique pour traiter des douleurs associees a l'activite ou la contracture musculaire
CA002590540A Expired - Lifetime CA2590540C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique d'une toxine botulinique pour le traitement de secretions muqueuses excessives

Country Status (1)

Country	Link
CA (6)	CA2590293C (fr)

1994
- 1994-12-16 CA CA002590293A patent/CA2590293C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002589987A patent/CA2589987C/fr not_active Expired - Fee Related
- 1994-12-16 CA CA002590537A patent/CA2590537C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002589989A patent/CA2589989C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002589968A patent/CA2589968A1/fr not_active Abandoned
- 1994-12-16 CA CA002590540A patent/CA2590540C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2589987A1 (fr)	1995-07-06
CA2589989C (fr)	2009-05-12
CA2589987C (fr)	2008-05-20
CA2590537A1 (fr)	1995-07-06
CA2590540A1 (fr)	1995-07-06
CA2589968A1 (fr)	1995-07-06
CA2590540C (fr)	2009-05-05
CA2590537C (fr)	2009-10-13
CA2589989A1 (fr)	1995-07-06
CA2590293C (fr)	2009-05-12

Similar Documents

Publication	Publication Date	Title
CA2180011A1 (fr)	1995-07-06	Toxines botulinum utilisees dans le traitement de divers troubles, et douleurs associees
WO1995017904B1 (fr)	1995-12-07	Toxines botulinum utilisees dans le traitement de divers troubles, et douleurs associees
CA2164866A1 (fr)	1994-12-22	Traitement de troubles et de maladies neuromusculaires a l'aide de differents serotypes de botulinum
CA2190011A1 (fr)	1995-11-16	Procede de reduction des maux de tete
JP2004518632A5 (fr)	2008-10-23
CA2164626A1 (fr)	1994-12-22	Toxines multiples de botulinum pour le traitement des troubles neuromusculaires
PT923293E (pt)	2005-03-31	Tratamento da diarreia
CA2164291A1 (fr)	1994-12-22	Methodes et compositions pharmaceutiques utiles pour le traitement de troubles neurologiques
EP1011695A4 (fr)	2004-05-26	Therapie a base de neurotoxines pour le traitement de troubles urologiques et de troubles connexes
WO2003068171A3 (fr)	2003-09-25	Procede et composition pour le traitement d'une inflammation et de troubles neurologiques associes au sida
GB9120306D0 (en)	1991-11-06	Method and compositions for the treatment of cerebral palsy
GB9205800D0 (en)	1992-04-29	Treatment of fibrotic disorders
CA2245661A1 (fr)	1997-08-21	Traitement de la sclerose en plaques
CA2275167A1 (fr)	1998-06-25	Utilisation locale d'agonistes opioides kappa dans le traitement de la douleur oculaire
WO2002039999B1 (fr)	2004-04-15	Inhibition d'angiogenese du type endostatine
WO2003070175A3 (fr)	2004-04-08	Utilisation d'un compose opioide pour le traitement d'un trouble neurologique ou neurogene
CA2136953A1 (fr)	1993-12-09	Methode d'utilisation d'un inhibiteur de la coagulation associe a une lipoproteine pour le traitement d'une septicemie
CA2590293A1 (fr)	1995-07-06	Utilisation du composant neurotoxique du botulinum pour le traitement d'un muscle spastique
CA2300766A1 (fr)	1995-07-06	Methode pour traiter une secretion cholinergique influencee
Iragui et al.	1991	Self-abatement of simple partial epileptic seizures
WO1998001125A3 (fr)	1998-05-07	Isomeres dextrogyres d'oxybutynine et de desethyloxybutynine utilises dans le traitement de l'hyperactivite gastro-intestinale
EP0182569A3 (en)	1987-10-14	Use of 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyridoû1,2-a¨pyrimidine-3-carboxamide for the prevention and treatment of gastrointestinal damages
Chen	1997	Treatment of apoplectic hemiplegia by digital acupoint pressure--a report of 42 cases
WO1999065511A3 (fr)	2000-03-02	COMPOSITION ET PROCEDE DE TRAITEMENT D'UNE INFECTION PAR $i(PSEUDOMONAS)
WO1996029076A3 (fr)	1997-02-13	Traitement des affections instestinales inflammatoires par la cotinine

Legal Events

Date	Code	Title	Description
2007-06-07	EEER	Examination request
2015-02-17	MKEX	Expiry	Effective date: 20141216